MA27311A1 - USE OF CETP INHIBITORS AND OPTIONALLY HMG-COA-REDUCTASE INHIBITORS AND / OR ANTIHYPERTENSITIVE AGENTS - Google Patents
USE OF CETP INHIBITORS AND OPTIONALLY HMG-COA-REDUCTASE INHIBITORS AND / OR ANTIHYPERTENSITIVE AGENTSInfo
- Publication number
- MA27311A1 MA27311A1 MA28016A MA28016A MA27311A1 MA 27311 A1 MA27311 A1 MA 27311A1 MA 28016 A MA28016 A MA 28016A MA 28016 A MA28016 A MA 28016A MA 27311 A1 MA27311 A1 MA 27311A1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- agents
- antihypertensitive
- coa
- cetp
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 abstract 1
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 abstract 1
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 abstract 1
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 abstract 1
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
Abstract
DEPOSANT Société dite : PFIZER PRODUCTS INC. REVENDICATION DE PRIORITES US 2 Juillet 2002 60/393,395 Utilisation d'inhibiteurs de CETP et facultativement d'inhibiteurs de HMG-CoA-réductase et/ou d'agents antihypertensifs La présente invention concerne des inhibiteurs de la protéine de transfert d'ester de cholestérol (CETP), des compositions pharmaceutiques contenant ces inhibiteurs, et l'utilisation de ces inhibiteurs pour le traitement de certaines maladies/affections éventuellement en association avec certains agents thérapeutiques, par exemple des agents anti-hypertensifs.DEPOSITOR Company known as: PFIZER PRODUCTS INC. The present invention relates to inhibitors of the cholesterol ester transfer protein. (CETP), pharmaceutical compositions containing these inhibitors, and the use of these inhibitors for the treatment of certain diseases / conditions possibly in combination with certain therapeutic agents, for example antihypertensive agents.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39339502P | 2002-07-02 | 2002-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27311A1 true MA27311A1 (en) | 2005-05-02 |
Family
ID=30115572
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28016A MA27311A1 (en) | 2002-07-02 | 2004-12-17 | USE OF CETP INHIBITORS AND OPTIONALLY HMG-COA-REDUCTASE INHIBITORS AND / OR ANTIHYPERTENSITIVE AGENTS |
Country Status (23)
Country | Link |
---|---|
US (1) | US20040053842A1 (en) |
EP (1) | EP1519754A1 (en) |
JP (1) | JP2005532388A (en) |
KR (1) | KR20050025578A (en) |
CN (1) | CN1665537A (en) |
AP (1) | AP2004003189A0 (en) |
AU (1) | AU2003244921A1 (en) |
BR (1) | BR0312421A (en) |
CA (1) | CA2488736A1 (en) |
EA (1) | EA200401471A1 (en) |
EC (1) | ECSP045520A (en) |
HR (1) | HRP20041238A2 (en) |
IL (1) | IL165328A0 (en) |
IS (1) | IS7570A (en) |
MA (1) | MA27311A1 (en) |
MX (1) | MXPA05000015A (en) |
NO (1) | NO20050497L (en) |
OA (1) | OA12876A (en) |
PL (1) | PL374878A1 (en) |
TN (1) | TNSN04268A1 (en) |
TW (1) | TW200401768A (en) |
WO (1) | WO2004004778A1 (en) |
ZA (1) | ZA200409582B (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
AU2003283769A1 (en) * | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
BR0317593A (en) * | 2002-12-20 | 2005-11-22 | Pfizer Prod Inc | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
GEP20084540B (en) | 2003-01-14 | 2008-11-25 | Arena Pharm Inc | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
MXPA05009976A (en) * | 2003-03-17 | 2005-11-04 | Japan Tobacco Inc | Method for increasing the oral bioavailability of s-`2- (``1-(2- ethylbutyl) cyclohexyl! carbonyl! amino) phenyl!-2- methylpropanethioate. |
EP2289507A1 (en) * | 2003-03-17 | 2011-03-02 | Japan Tobacco, Inc. | Pharmaceutical compositions of CETP inhibitors |
TWI393560B (en) * | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | Combination comprising s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]2-methylpropanethioate and an hmg coa reductase inhibitor |
GEP20084406B (en) * | 2003-05-30 | 2008-06-25 | Ranbaxy Lab Ltd | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
TWI335328B (en) | 2003-07-14 | 2011-01-01 | Arena Pharm Inc | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto |
RU2006125512A (en) * | 2003-12-16 | 2008-01-27 | Новартис АГ (CH) | APPLICATION OF STATINS FOR TREATMENT OF METABOLIC SYNDROME |
KR20070002085A (en) * | 2004-04-07 | 2007-01-04 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
US20060063803A1 (en) * | 2004-09-23 | 2006-03-23 | Pfizer Inc | 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds |
WO2007115131A2 (en) * | 2006-03-29 | 2007-10-11 | Guilford F Timothy | Liposomal reduced glutathione and 1-arginine, including other ingredient(s) |
AU2005305460B2 (en) * | 2004-11-22 | 2011-04-21 | Dexcel Pharma Technologies Ltd. | Stable atorvastatin formulations |
MX2007006777A (en) * | 2004-12-06 | 2007-08-06 | Avigen Inc | Ibudilast for treating neuropathic pain and associated syndromes. |
US7700774B2 (en) * | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
US20080305158A1 (en) * | 2004-12-28 | 2008-12-11 | Ranbaxy Laboratories Limited | Methods For the Preparation of Stable Pharmaceutical Solid Dosage Forms of Atorvastatin and Amlodipine |
CA2605214C (en) | 2004-12-31 | 2016-07-12 | Reddy Us Therapeutics, Inc. | Benzylamine derivatives as cetp inhibitors |
US8604055B2 (en) * | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
MY148521A (en) | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
WO2007106111A2 (en) * | 2005-07-01 | 2007-09-20 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising nilvadipine |
WO2007005941A2 (en) | 2005-07-05 | 2007-01-11 | President And Fellows Of Harvard College | Liver targeted conjugates |
AU2006313430B2 (en) * | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
AR059838A1 (en) * | 2006-03-14 | 2008-04-30 | Ranbaxy Lab Ltd | FORMULATIONS FOR STABILIZING DOSES OF STATIN |
WO2007116243A2 (en) * | 2006-04-10 | 2007-10-18 | Mintails Limited | Method for treating fibromyalgia and related conditions |
CN101494980A (en) * | 2006-07-14 | 2009-07-29 | 兰贝克赛实验室有限公司 | Polymorphic forms of an HMG-CoA reductase inhibitor and uses thereof |
EP2131841B1 (en) * | 2007-01-30 | 2012-08-01 | Avigen, Inc. | Methods for treating acute pain |
WO2008137012A1 (en) * | 2007-05-03 | 2008-11-13 | Avigen, Inc. | Use of a glial attenuator to prevent amplified pain responses caused by glial priming |
EP2158333A4 (en) * | 2007-05-14 | 2010-12-29 | Synvista Therapeutics Inc | Use of haptoglobin genotyping in diagnosis and treatment of defective reverse cholesterol transport (rct) |
WO2009021113A1 (en) * | 2007-08-09 | 2009-02-12 | Holtzman, Jordan, L. | Methods for enhancing glutahione peroxidase activity |
EP2070520A1 (en) | 2007-12-11 | 2009-06-17 | LEK Pharmaceuticals D.D. | Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media |
WO2012046681A1 (en) * | 2010-10-04 | 2012-04-12 | 興和株式会社 | Agent for inhibiting expression of lipid metabolism related mrna |
CA2812061A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP2744803A2 (en) | 2011-08-18 | 2014-06-25 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors |
JP6140168B2 (en) | 2011-09-27 | 2017-05-31 | ドクター レディズ ラボラトリーズ リミテッド | 5-Benzylaminomethyl-6-aminopyrazolo [3,4-B] pyridine derivatives as cholesteryl ester transfer protein (CETP) inhibitors useful for the treatment of atherosclerosis |
US10300059B2 (en) * | 2014-08-28 | 2019-05-28 | Dezima Pharma B.V. | Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
KR102603199B1 (en) | 2015-06-22 | 2023-11-16 | 아레나 파마슈티칼스, 인크. | (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta for use in S1P1 receptor-related disorders [B]Indole-3-yl)crystalline L-arginine salt of acetic acid (Compound 1) |
CA3032229A1 (en) * | 2016-07-27 | 2018-02-01 | Hartis-Pharma Sa | Therapeutic combinations to treat red blood cell disorders |
MX2019009841A (en) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compounds and methods for treatment of primary biliary cholangitis. |
CN116196314B (en) * | 2023-05-04 | 2023-08-15 | 广州市妇女儿童医疗中心 | Application of RI-1 or salt thereof in preparation of medicine for preventing and treating gastrointestinal diseases |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6144790A (en) * | 1997-02-07 | 2000-11-07 | Bledin; Anthony G | Contact fiber optic impact sensor |
GT199800127A (en) * | 1997-08-29 | 2000-02-01 | THERAPEUTIC COMBINATIONS. | |
CN1117566C (en) * | 1997-08-29 | 2003-08-13 | 辉瑞产品公司 | Combination therapy comprising amlodipine and a statin compound |
GT199800126A (en) * | 1997-08-29 | 2000-01-29 | COMBINATION THERAPY. | |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
GT199900147A (en) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- TETRAHIDROQUINOLINAS 2-SUBSTITUTED 4-AMINO SUBSTITUTED. | |
CZ20014229A3 (en) * | 1999-05-27 | 2003-01-15 | Pfizer Products Inc. | Common prodrugs of amlodipine and atorvastatin |
HN2000000050A (en) * | 1999-05-27 | 2001-02-02 | Pfizer Prod Inc | MUTUAL SALT OF AMLODIPINO AND ATORVASTATINA |
US20030092745A1 (en) * | 2000-02-25 | 2003-05-15 | Pfizer Inc. | Combination therapy |
US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
AU2001270937A1 (en) * | 2000-08-15 | 2002-02-25 | Pfizer Products Inc. | Therapeutic combination |
US6737430B2 (en) * | 2000-11-09 | 2004-05-18 | Pfizer, Inc. | Mutual prodrug of amlodipine and atorvastatin |
JP4334233B2 (en) * | 2001-04-11 | 2009-09-30 | アセロジエニクス・インコーポレイテツド | Method for increasing plasma HDL cholesterol levels and improving HDL functionality with probucol monoester |
US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
-
2003
- 2003-06-10 US US10/459,683 patent/US20040053842A1/en not_active Abandoned
- 2003-06-18 PL PL03374878A patent/PL374878A1/en not_active Application Discontinuation
- 2003-06-18 IL IL16532803A patent/IL165328A0/en unknown
- 2003-06-18 EP EP03738394A patent/EP1519754A1/en not_active Withdrawn
- 2003-06-18 MX MXPA05000015A patent/MXPA05000015A/en not_active Application Discontinuation
- 2003-06-18 JP JP2004519080A patent/JP2005532388A/en not_active Withdrawn
- 2003-06-18 CA CA002488736A patent/CA2488736A1/en not_active Abandoned
- 2003-06-18 AP AP2004003189A patent/AP2004003189A0/en unknown
- 2003-06-18 KR KR1020057000061A patent/KR20050025578A/en not_active Application Discontinuation
- 2003-06-18 AU AU2003244921A patent/AU2003244921A1/en not_active Abandoned
- 2003-06-18 WO PCT/IB2003/002792 patent/WO2004004778A1/en not_active Application Discontinuation
- 2003-06-18 BR BR0312421-5A patent/BR0312421A/en not_active IP Right Cessation
- 2003-06-18 OA OA1200400342A patent/OA12876A/en unknown
- 2003-06-18 EA EA200401471A patent/EA200401471A1/en unknown
- 2003-06-18 CN CN038155753A patent/CN1665537A/en active Pending
- 2003-07-01 TW TW092117985A patent/TW200401768A/en unknown
-
2004
- 2004-11-26 ZA ZA200409582A patent/ZA200409582B/en unknown
- 2004-11-29 IS IS7570A patent/IS7570A/en unknown
- 2004-12-17 MA MA28016A patent/MA27311A1/en unknown
- 2004-12-30 HR HR20041238A patent/HRP20041238A2/en not_active Application Discontinuation
- 2004-12-30 TN TNP2004000268A patent/TNSN04268A1/en unknown
- 2004-12-30 EC EC2004005520A patent/ECSP045520A/en unknown
-
2005
- 2005-01-28 NO NO20050497A patent/NO20050497L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HRP20041238A2 (en) | 2005-06-30 |
BR0312421A (en) | 2005-04-19 |
TW200401768A (en) | 2004-02-01 |
US20040053842A1 (en) | 2004-03-18 |
CA2488736A1 (en) | 2004-01-15 |
AU2003244921A1 (en) | 2004-01-23 |
EP1519754A1 (en) | 2005-04-06 |
TNSN04268A1 (en) | 2007-03-12 |
AP2004003189A0 (en) | 2004-12-31 |
NO20050497L (en) | 2005-03-08 |
EA200401471A1 (en) | 2005-06-30 |
IS7570A (en) | 2004-11-29 |
CN1665537A (en) | 2005-09-07 |
ZA200409582B (en) | 2006-08-30 |
MXPA05000015A (en) | 2005-04-08 |
OA12876A (en) | 2006-09-15 |
JP2005532388A (en) | 2005-10-27 |
WO2004004778A1 (en) | 2004-01-15 |
KR20050025578A (en) | 2005-03-14 |
PL374878A1 (en) | 2005-11-14 |
ECSP045520A (en) | 2005-03-10 |
IL165328A0 (en) | 2006-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27311A1 (en) | USE OF CETP INHIBITORS AND OPTIONALLY HMG-COA-REDUCTASE INHIBITORS AND / OR ANTIHYPERTENSITIVE AGENTS | |
MA26688A1 (en) | 4-CARBOXAMINO-2-SUBSTITUE-1,2,3,4-TETRAHYDROQUINOLEINS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
TNSN07063A1 (en) | THERAPEUTIC USES OF RTP801 INHIBITORS | |
EA200100872A1 (en) | COMPOSITION VALDEKOKSIBA | |
JO3404B1 (en) | Liquid pharmaceutical composition containing an erythropoietin derivative | |
MA26956A1 (en) | PYRIMIDINE-2,4,6, TRIONES INHIBITORS OF METALLOPROTEINASES. | |
MXPA04005790A (en) | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase. | |
NO20050851L (en) | Caspase Inhibitors and Uses thereof | |
NO20042596L (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
EP1562897A4 (en) | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease | |
NO20052739L (en) | CCR5 antagonists as drugs | |
ATE405269T1 (en) | CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS | |
YU49202A (en) | Benzazole derivatives and their use as jnk modulators | |
AU2003296992A1 (en) | Pyrrolidine and azetidine compounds as ccr5 antagonists | |
FI964332A (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
HUP0001632A2 (en) | Pharmaceutical compositions comprising selective phosphodiestherase inhibitors | |
MA27730A1 (en) | COMBINATIONS OF PAROXETINE AND 4- (S) - (4-ACETYL-PIPERAZIN-1-YL) -2- (R) - (4-FLUORO-2-METHYL-PHENYL) -PIPERIDINE-1-CARBOXYLIC ACID [1 - (R) - (3,5-BIS-TRIFLUOROMETHYL-PHENYL) -ETHYL] -METHYLAMIDE FOR THE TREATMENT OF DEPRESSION AND / OR ANXIETY | |
MXPA05013226A (en) | Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase. | |
BG105342A (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases | |
RS44304A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
DE69512940D1 (en) | N-HYDROXY-UREA DERIVATIVES AS AN INFLAMMATORY-RESISTANT AGENT | |
DE60306503D1 (en) | STATIN THERAPY FOR IMPROVING THE MAINTENANCE OF COGNITIVE FUNCTION | |
MA28224A1 (en) | NITRO-OXIDINE DRUGS AGAINST HYPERTENSION. | |
AP9801417A0 (en) | Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders. | |
BG105984A (en) | Osanetant in the treatment of mood disorders |